Related Experiment Video
Updated: Jul 19, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Antiarrhythmic properties of estrogens
A I Matyushin1, N V Kaverina, N L Shimanovskii
1Department of Molecular Pharmacology and Radiobiology, Medical and Biological Faculty, Russian State Medical University, Moscow.
Bulletin of Experimental Biology and Medicine
|November 1, 2006
Summary
Estrone, estriol, and estradiol valerate showed antiarrhythmic effects in rats. Estrone demonstrated the strongest efficacy in treating aconitine-induced arrhythmia, suggesting potential therapeutic applications.
Area of Science:
- Pharmacology
- Cardiovascular Science
Background:
- Cardiac arrhythmias are a significant cause of mortality.
- Estrogens are known to have cardiovascular effects, but their direct antiarrhythmic properties require further investigation.
Purpose of the Study:
- To evaluate the potential antiarrhythmic activity of specific estrogen compounds.
- To compare the efficacy of estrone, estriol, and estradiol valerate in a rat model of induced arrhythmia.
Main Methods:
- Aconitine was used to induce cardiac arrhythmia in rats.
- The antiarrhythmic effects of intravenously administered estrone, estriol, and estradiol valerate were assessed.
- Efficacy was determined by the ability to prevent or reverse arrhythmic events.
Main Results:
- Estrone, estriol, and estradiol valerate all exhibited significant antiarrhythmic activity.
- Estrone was found to be the most potent antiarrhythmic agent among the tested compounds.
- The observed effects suggest a direct role of these estrogens in regulating cardiac rhythm.
Conclusions:
- Estrone, estriol, and estradiol valerate possess notable antiarrhythmic properties.
- Estrone shows particular promise as a therapeutic agent for certain types of cardiac arrhythmias.
- Further research into the mechanisms underlying estrogen-mediated antiarrhythmic effects is warranted.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...